Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PTGX
HoldPremium GrowerProtagonist Therapeutics, Inc. · Healthcare · United States · $9.3B · Avg Vol: $72M/d
COMPANY DESCRIPTION
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative oral peptide therapeutics for gastrointestinal and hematology disorders. The company's competitive moat is built upon its proprietary technology platform, which enables the oral delivery of therapeutic peptides, addressing a significant challenge in drug development and potentially offering first-in-class treatments for unmet medical needs. Its focused pipeline aims to revolutionize treatment options for chronic diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.6M | 60.0M | 434.4M | 46.0M | 20.1% | 282.0M | 542.3M | 203.4M | 110.2% |
| EPS | -2.60 | -1.39 | 4.47 | -2.05 | — | 1.03 | — | — | — |
| Shares | 49.3M | 57.7M | 61.0M | 62.6M | +26.8% | 64.7M | — | — | — |
| Debt | 3.7M | 1.1M | 10.9M | 10.3M | 41.3% | 9.2M | — | — | — |
| Equity | 215.6M | 336.7M | 675.3M | 614.7M | 41.8% | — | — | — | — |
| Op CF | -108.1M | -70.2M | 184.2M | 57.7M | -68.7% | 131.2M | — | — | — |
| Inv CF | 91.5M | -39.3M | -299.5M | -49.3M | — | — | — | — | — |
| Fin CF | 18.8M | 170.5M | 25.9M | 22.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PTGX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc.(you) | $9.3B | 44 | Hold |
| BLTE | Belite Bio, Inc | $6.1B | 42 | Hold |
| APGE | Apogee Therapeutics, Inc. | $10.2B | 32 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 31 | Sell |
| TGTX | TG Therapeutics, Inc. | $8.3B | 57 | Hold |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 33 | Sell |
| PCVX | Vaxcyte, Inc. | $8.9B | 28 | Sell |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.3B | 31 | Sell |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.0B | 24 | Sell |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%